Common Vascular Toxicities of Cancer Therapies

Area of Science:

• Oncology
• Cardiovascular Medicine
• Pharmacology

Background:

• Targeted cancer therapies offer molecular specificity for improved efficacy and safety.
• Paradoxically, these agents have highlighted toxicities, including cardiac and vascular adverse events.
• Vascular toxicities extend beyond venous thromboembolism, encompassing diverse presentations.

Purpose of the Study:

• To provide an overview of common vascular toxicities associated with targeted cancer therapies.
• To discuss the spectrum of vascular presentations and underlying pathomechanisms.
• To outline current management strategies for these adverse events.

Main Methods:

• Literature review of targeted cancer agents and their associated vascular toxicities.
• Analysis of reported vascular presentations, including abnormal vascular reactivity, thrombosis, and atherosclerosis.
• Synthesis of management guidelines and treatment approaches.

Main Results:

• Targeted therapies can induce a wide range of vascular toxicities affecting various vascular territories.
• Pathomechanisms include altered vascular reactivity, acute thrombosis, and accelerated atherosclerosis.
• Management requires a multidisciplinary approach tailored to the specific presentation.

Conclusions:

• Vascular toxicities are a significant concern with targeted cancer therapies, necessitating careful monitoring.
• Understanding the diverse presentations and mechanisms is crucial for effective patient management.
• Proactive identification and management strategies can mitigate the impact of these adverse events.